Non small cell lung cancer medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 8: Line 8:


{{NSCLC stage III medical therapy}}
{{NSCLC stage III medical therapy}}
==Chemotherapeutic regimens==
Shown below is a table depicting the different choices of regimens for the initial or adjuvant chemotherapy of patients with non-small cell lung cancer. The list of regimens has been adapted from the 2014 NCCN Non-Small Cell Lung Cancer guidelines.<ref name="NCCN">http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ref>
===Cisplatin based therapy===
{|Border="1"
|-
! Agent !! Recommended regimen
|-
| [[Cisplatin]] 50 mg/m<sup>2</sup> + [[vinorelbine]] 25 mg/m<sup>2</sup> || [[Cisplatin]] on days 1 and 8, [[vinorelbine]] on days 1, 8, 15, 22 and every 28 days to a total of 4 cycles
|-
| [[Cisplatin]] 100 mg/m<sup>2</sup> + [[vinorelbine]] 30 mg/m<sup>2</sup> || [[Cisplatin]] on day 1, [[vinorelbine]] on days 1, 8, 15, 22 and every 28 days to a total of 4 cycles
|-
| [[Cisplatin]] 75-80 mg/m<sup>2</sup> + [[vinorelbine]] 25-50 mg/m<sup>2</sup> || [[Cisplatin]] on day 1, [[vinorelbine]] on days 1, 8 and every 21 days to a total of 4 cycles
|-
| [[Cisplatin]] 80 mg/m<sup>2</sup> + [[vinorelbine]] 4 mg/m<sup>2</sup> || [[Cisplatin]] on days 1, 22, 43, 64, then every 21 days to a total of 4 cycles, [[vinorelbine]] on days 1, 8, 15, 22, 29, every 2 weeks after day 43 until the completion of [[cisplatin]] treatmet
|-
| [[Cisplatin]] 100 mg/m<sup>2</sup> + [[etoposide]] 100 mg/m<sup>2</sup> || [[Cisplatin]] on day 1, [[etoposide]] through days 1 to 3 and every 28 days to a total of 4 cycles
|-
| [[Cisplatin]] 75 mg/m<sup>2</sup> + [[gemcitabine]] 1250 mg/m<sup>2</sup> || [[Cisplatin]] on day 1, [[gemcitabine]] on days 1, 8 and every 21 days to a total of 4 cycles
|-
| [[Cisplatin]] 75 mg/m<sup>2</sup> + [[docetaxel]] 75 mg/m<sup>2</sup> || [[Cisplatin]] on day 1, [[docetaxel]] on day 1 and every 21 days to a total of 4 cycles
|-
| [[Cisplatin]] 50 mg/m<sup>2</sup> + [[pemetrexed]] 500 mg/m<sup>2</sup> || [[Cisplatin]] on day 1, [[pemetrexed]] on days 1 and every 21 days to a total of 4 cycles
|-
|}
===Alternative regimen: patients with comorbidities or can't tolerate cisplatin===
Paclitaxel 200 mg/m<sup>2</sup> on day 1  + carboplatin area under the concentration (AUC) 6 on day 1 and then every 21 days.<ref name="NCCN">http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf</ref>
==Chemotherapy plus radiotherapy regimens==
==Chemotherapy plus radiotherapy regimens==


Revision as of 15:41, 24 June 2014

Small Cell Carcinoma of the Lung Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Small Cell Carcinoma of the Lung from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Radiation Therapy

Surgery

Prevention

Future or Investigational Therapies

Case Studies

Case #1

Non small cell lung cancer medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non small cell lung cancer medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non small cell lung cancer medical therapy

CDC on Non small cell lung cancer medical therapy

Non small cell lung cancer medical therapy in the news

Blogs on Non small cell lung cancer medical therapy

Directions to Hospitals Treating Small cell carcinoma of the lung

Risk calculators and risk factors for Non small cell lung cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alonso Alvarado, M.D. [2]

Overview

Chemotherapy plus radiotherapy regimens

Chemotherapy plus radiotherapy

The list bellow show the options for concomitant chemotherapy plus radiation therapy based on the 2014 NCCN Non-Small Cell Lung Cancer guidelines.[1]


  • Cisplatin 50 mg/m2 on days 1, 8, 29 and 36 + etoposide 50 mg/m2 through days 1 to 5 and then 29 to 33 + thoracic radiotherapy
  • Cisplatin 100 mg/m2 on days 1 and 29 + vinblastin 5 mg/m2 weekly for 5 weeks + thoracic radiotherapy
  • Cisplatin 75 mg/m2 on the first day + pemetrexed 500 mg/m2 on day 1 and then every 21 days to a total of 3 cycles + thoracic radiotherapy
  • Carboplatin (AUC) 5 on the first day + pemetrexed 500 mg/m2 on day 1 and then every 21 days to a total of 3 cycles + thoracic radiotherapy

Chemotherapy followed by radiotherapy

Chemotherapy plus radiotherapy, followed by chemotherapy

References

  1. ↑ http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Non_small_cell_lung_cancer_medical_therapy&oldid=981535"